• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一名70岁女性罕见的ALK阳性组织细胞增多症伴神经系统受累病例,经部分切除和阿来替尼治疗成功。

A rare case of ALK-positive histiocytosis with neurological involvement in a 70-year-old woman successfully managed with partial resection and alectinib.

作者信息

So Eiichiro, Ishida Norihito, Chida Akihiko, Horie Sara, Kishimoto Shotaro, Tsugaru Kai, Hayashi Hideyuki, Koda Yuya, Ozaki Masahiro, Okita Hajime, Kanai Takanori, Hirata Kenro

机构信息

Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.

Keio Cancer Center, Keio University School of Medicine, Tokyo, Japan.

出版信息

Int Cancer Conf J. 2025 Jun 3;14(3):327-334. doi: 10.1007/s13691-025-00776-9. eCollection 2025 Jul.

DOI:10.1007/s13691-025-00776-9
PMID:40625769
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12229379/
Abstract

Anaplastic lymphoma kinase (ALK)-positive histiocytosis is a recently classified rare subtype of histiocytic neoplasm, characterized by ALK immunoreactivity due to gene rearrangement. Most reported cases have developed in infants and middle-aged individuals, with effective ALK inhibition. The clinicopathological spectrum remains uncharacterized because of few reported cases. Herein, we report a case of a 70-year-old woman diagnosed with ALK-positive histiocytosis involving the nervous system, successfully treated with partial surgical resection and alectinib administration. To the best of our knowledge, this is the oldest patient reported with this condition with nervous system involvement, expanding our understanding of its clinicopathological spectrum.

摘要

间变性淋巴瘤激酶(ALK)阳性组织细胞增多症是一种最近分类的罕见组织细胞肿瘤亚型,其特征是由于基因重排导致ALK免疫反应性。大多数报道的病例发生在婴儿和中年个体中,对ALK抑制有效。由于报道的病例较少,其临床病理谱仍未明确。在此,我们报告一例70岁女性被诊断为ALK阳性组织细胞增多症累及神经系统,经部分手术切除和给予阿来替尼成功治疗。据我们所知,这是报道的患有这种累及神经系统疾病的最年长患者,扩展了我们对其临床病理谱的认识。

相似文献

1
A rare case of ALK-positive histiocytosis with neurological involvement in a 70-year-old woman successfully managed with partial resection and alectinib.一名70岁女性罕见的ALK阳性组织细胞增多症伴神经系统受累病例,经部分切除和阿来替尼治疗成功。
Int Cancer Conf J. 2025 Jun 3;14(3):327-334. doi: 10.1007/s13691-025-00776-9. eCollection 2025 Jul.
2
Targeted therapy for advanced anaplastic lymphoma kinase (<I>ALK</I>)-rearranged non-small cell lung cancer.晚期间变性淋巴瘤激酶(<I>ALK</I>)重排非小细胞肺癌的靶向治疗。
Cochrane Database Syst Rev. 2022 Jan 7;1(1):CD013453. doi: 10.1002/14651858.CD013453.pub2.
3
First-line lorlatinib treatment in a 19-year-old patient with ALK-rearranged pulmonary large-cell neuroendocrine carcinoma: a case report and literature review.19岁间变性淋巴瘤激酶(ALK)重排肺大细胞神经内分泌癌患者的一线劳拉替尼治疗:病例报告及文献综述
Anticancer Drugs. 2025 Jul 7. doi: 10.1097/CAD.0000000000001754.
4
Systematic review and network meta-analysis of lorlatinib with comparison to other anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) as first-line treatment for ALK-positive advanced non-smallcell lung cancer (NSCLC).洛拉替尼与其他间变性淋巴瘤激酶(ALK)酪氨酸激酶抑制剂(TKI)作为一线治疗ALK 阳性晚期非小细胞肺癌(NSCLC)的比较:系统评价和网络荟萃分析。
Lung Cancer. 2024 Nov;197:107968. doi: 10.1016/j.lungcan.2024.107968. Epub 2024 Sep 29.
5
Alk-positive anaplastic large cell Lymphoma: First documented case of primary mandibular involvement in a 12-Year-Old male.ALK阳性间变性大细胞淋巴瘤:首例12岁男性原发性下颌骨受累的记录病例。
Oral Oncol. 2025 Aug;167:107452. doi: 10.1016/j.oraloncology.2025.107452. Epub 2025 Jun 27.
6
Carbamazepine versus phenytoin monotherapy for epilepsy: an individual participant data review.卡马西平与苯妥英钠单药治疗癫痫:个体参与者数据回顾
Cochrane Database Syst Rev. 2017 Feb 27;2(2):CD001911. doi: 10.1002/14651858.CD001911.pub3.
7
Comparison of lorlatinib, alectinib and brigatinib in ALK inhibitor-naive/untreated ALK-positive advanced non-small-cell lung cancer: a systematic review and network meta-analysis.劳拉替尼、阿来替尼和布加替尼在初治/未治疗的ALK阳性晚期非小细胞肺癌中的比较:一项系统评价和网状Meta分析
J Chemother. 2022 Apr;34(2):87-96. doi: 10.1080/1120009X.2021.1937782. Epub 2021 Jun 17.
8
Anaplastic lymphoma kinase inhibitor therapy in the treatment of inflammatory myofibroblastic tumors in pediatric patients: Case reports and literature review.间变性淋巴瘤激酶抑制剂治疗儿科炎性肌纤维母细胞瘤病例报告及文献复习。
J Pediatr Surg. 2021 Dec;56(12):2364-2371. doi: 10.1016/j.jpedsurg.2021.02.004. Epub 2021 Feb 11.
9
Identifying optimal ALK inhibitors in first- and second-line treatment of patients with advanced ALK-positive non-small-cell lung cancer: a systematic review and network meta-analysis.识别晚期 ALK 阳性非小细胞肺癌一线和二线治疗中最优的 ALK 抑制剂:系统评价和网络荟萃分析。
BMC Cancer. 2024 Feb 8;24(1):186. doi: 10.1186/s12885-024-11916-4.
10
Cutaneous Rhabdomyosarcoma With FUS::TFCP2 Fusion: An Emerging Entity That Expands the Differential Diagnosis of ALK-Positive Spindle Cell Neoplasm of the Skin.伴有FUS::TFCP2融合的皮肤横纹肌肉瘤:一种新兴实体,扩大了皮肤ALK阳性梭形细胞瘤的鉴别诊断范围。
Am J Dermatopathol. 2025 Jun 26. doi: 10.1097/DAD.0000000000003031.